Biondo Investment Advisors LLC reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 79.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,551 shares of the life sciences company's stock after selling 54,615 shares during the quarter. Biondo Investment Advisors LLC's holdings in Illumina were worth $1,154,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Diversified Trust Co bought a new position in shares of Illumina during the first quarter valued at $355,000. State of Alaska Department of Revenue lifted its holdings in shares of Illumina by 2.5% during the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company's stock valued at $1,469,000 after purchasing an additional 445 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Illumina by 4.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 199,176 shares of the life sciences company's stock valued at $15,803,000 after purchasing an additional 9,252 shares in the last quarter. Merit Financial Group LLC lifted its holdings in shares of Illumina by 344.8% during the first quarter. Merit Financial Group LLC now owns 13,036 shares of the life sciences company's stock valued at $1,034,000 after purchasing an additional 10,105 shares in the last quarter. Finally, Citigroup Inc. increased its position in Illumina by 13.5% during the first quarter. Citigroup Inc. now owns 150,764 shares of the life sciences company's stock valued at $11,962,000 after acquiring an additional 17,985 shares during the last quarter. 89.42% of the stock is owned by institutional investors.
Illumina Stock Performance
ILMN traded down $2.14 during midday trading on Monday, reaching $99.66. The company had a trading volume of 1,686,401 shares, compared to its average volume of 1,884,578. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average of $98.37 and a two-hundred day moving average of $88.56. The company has a market cap of $15.32 billion, a P/E ratio of 12.62, a P/E/G ratio of 2.29 and a beta of 1.37. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.12 billion. During the same quarter last year, the business posted $0.36 earnings per share. The firm's revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on ILMN shares. Stephens set a $110.00 target price on Illumina and gave the company an "overweight" rating in a report on Monday, August 4th. Morgan Stanley increased their target price on Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a report on Monday, August 4th. JPMorgan Chase & Co. lowered their target price on Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group increased their target price on Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a report on Friday, August 1st. Finally, Piper Sandler lowered their target price on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. Seven research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $124.58.
Read Our Latest Research Report on Illumina
Illumina Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
See Also
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access